Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Functional Exploration of Biosynthetic Dark Matter in the Human Gut Microbiome

Project description

Insight into the role of microbiota secondary metabolites

Gut microbiota have co-evolved with the host to facilitate homeostasis through complex host–microbe and microbe–microbe interactions. Scientists of the EU-funded RiPPs from the Gut project are interested in studying the microbiota from a functional perspective, focussing on microbial secondary metabolites or natural products (NPs). Using bioactivity assays and chemical proteomics, they will investigate the role and synthesis of different NPs from biosynthetic gene clusters in the most abundant gut bacteria. Emphasis will be placed on NPs of the ribosomally synthesised and post-translationally modified peptide (RiPP) family. The results will help decipher the possible therapeutic applications of these metabolites in syndromes associated with gut microbiota disturbance.

Objective

The human gut is the habitat for trillions of microbial cells living in synergy with each other and with the host. While metagenomic studies of the gut microbiome have provided a wealth of DNA sequence data, functional studies of gut bacteria remain challenging. To study the gut microbiome from a functional perspective, understanding host-microbe and microbe-microbe interactions is key. These contacts are often established by specialized molecules termed secondary metabolites or natural products (NPs). The machinery required to synthesize these metabolites is encoded in bacterial genomes by biosynthetic gene clusters (BCGs). Remarkably, even though 14,000 BGCs were identified in the human microbiota, very little is known about the identities and functions of their products. To address that, we will focus on NPs of the ribosomally synthesized and post-translationally modified peptide (RiPP) family, the second most abundant NP class in the human gut. The Piel group recently discovered unprecedented RiPPs with altered peptide backbones, challenging the paradigm that ribosomal synthesis is limited to the L-alpha-amino acid topology. These modifications include the excision of a tyramine moiety from a tyrosine-glycine motif, which introduces an alpha-keto-beta-amino acid in the peptide precursor backbone; and the epimerization of amino acids from L- to D-configuration. Enzymes homologous to these backbone-modifying catalysts and associated with RiPP gene clusters have been found bioinformatically in a wide variety of bacterial genomes, including gut microbiome representatives. The pervasiveness of these BGCs in microbiome bacteria suggests a function for these metabolites and possible therapeutic applications. This proposal aims to identify the products of these gene clusters in representatives of the most abundant phyla in the gut microbiome. In addition, we will examine the functions of the discovered metabolites utilizing bioactivity assays and chemical proteomics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Net EU contribution
€ 191 149,44
Address
Raemistrasse 101
8092 Zuerich
Switzerland
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 191 149,44